NCT06887452 Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout
| NCT ID | NCT06887452 |
| Status | Recruiting |
| Phase | — |
| Sponsor | VA Office of Research and Development |
| Condition | Gout |
| Study Type | INTERVENTIONAL |
| Enrollment | 310 participants |
| Start Date | 2026-10-01 |
| Primary Completion | 2029-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 310 participants in total. It began in 2026-10-01 with a primary completion date of 2029-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.
Eligibility Criteria
Inclusion Criteria: * US Veterans with physician-diagnosed * Documented hyperuricemia (SU \> 6.8 milligrams per deciliter) * Satisfy American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) gout classification criteria * Report 1 or more flares in the prior 6 months * Receipt of a new urate-lowering therapy (ULT) prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare/SU criteria Exclusion Criteria: * Any patient intolerant or unable to take urate-lowering therapies (allopurinol or febuxostat) * Patients with a rheumatology encounter within the prior 3 months * Patients on an allopurinol dose \> 300 or a Febuxostat dose \> 40 * Patients with stage IV/V Chronic Kidney Disease (CKD) * Patients with a life expectancy \< 12 months * Patients with a concomitant medication of azathioprine or 6-MPC (urate-lowering therapy contraindicated)
Contact & Investigator
Ted R. Mikuls
PRINCIPAL INVESTIGATOR
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Frequently Asked Questions
Who can join the NCT06887452 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gout. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06887452 currently recruiting?
Yes, NCT06887452 is actively recruiting participants. Contact the research team at bridget.kramer@va.gov for enrollment information.
Where is the NCT06887452 trial being conducted?
This trial is being conducted at Omaha, United States, Portland, United States, Philadelphia, United States, Salt Lake City, United States and 1 additional location.
Who is sponsoring the NCT06887452 clinical trial?
NCT06887452 is sponsored by VA Office of Research and Development. The principal investigator is Ted R. Mikuls at Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE. The trial plans to enroll 310 participants.